Abstract:Abstract Introduction: The fast-paced (immuno)-oncology drug development pipeline requires sophisticated and reliable in vitro models to accurately represent all players of complex human tumor microenvironment (TME). Our 3D Ex Vivo Patient Tissue (EVPT) platform is a short-term 3D ex vivo culture system utilizing ultra-fresh human tumor material processed to preserve the rich TME with high content image (HCI) analysis for higher throughput screening. The EVPT platform has previously been validated for standard of care (SoC) and immunological drug testing, including immune checkpoint inhibitors (ICI), in ovarian and non-small cell lung cancer (NSCLC) samples. Here, we present the expansion of the EVPT platform to other cancer indications, including resections from bladder, prostate, breast cancer, melanoma, glioblastoma (GBM) and hepatocellular carcinoma (HCC). Methods: Tumor tissues from NSCLC, ovarian, bladder, prostate, breast cancer, melanoma, GBM and HCC patients were processed within 24 hours. Freshly isolated tumor clusters were embedded in a protein-rich hydrogel and exposed to panels of (immuno)-oncology treatments at various doses in a 384-well format for 5-7 days. Phenotypic effects of treatment on morphological features, such as tumor cell killing, growth arrest, and immune cell proliferation, were measured using our proprietary automated HCI platform. Whole blood samples were also collected and PBMCs were isolated for autologous co-culture assays with selected cancer samples. Additionally, biomarkers analysis, including IHC, FACS and cytokine measurements, was performed. Results: At least two patient samples per new indication were processed. The success rate of the assay (30-40%) was primarily dependent on the sample quality, and the absence of necrotic, healthy, or fibrotic tissue within the sample. Panels of SoC drugs, targeted therapies, immunotherapies, and control compounds established for each indication were profiled per patient sample. For example, prostate cancer samples responded to Paclitaxel and Crizotinib, and one of GBM samples showed sensitivity to Regorafenib and Bevacizumab. Overall, similarly to clinical findings, about 20% of NSCLC and bladder cancer samples responded to ICI treatment, while 60-70% of the samples have responded to immunostimulatory controls (SEA and CD3/CD28).Although TME composition varied between NSCLC samples, IHC and FACs analysis showed a rich representation of immune compartment - T Cells (CD3+CD4+, CD3+CD8+), NK cells (CD16+), myeloid cells (CD14+, CD68+) alongside with EpCAM+ tumor cells. Conclusion: Despite tissue quality remaining a challenge for many primary ex vivo assays, the gentle processing and short-term 3D culturing in our EVPT platform preserves the rich TME in a wide range of tumors. This makes our EVPT platform an innovative and translational tool for complex (immuno)-oncology drug testing in multiple cancer indications. Citation Format: Nataliia Beztsinna, Sander Basten, Ezgi Kaya Aksoy, Niels Meesters, Stefanos Timiliotis, Donny van der Meer, Kuan Yan, Emma Spanjaard, Willemijn Vader, Leo S. Price. Expanding the 3D ex vivo patient tissue platform toolbox for (immuno)-oncology drug testing. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4570.

Abstract 6778: New microplate platform with cryopreserved 3D tumor spheroids for faster and convenient pre-clinical testing

Abstract B041: Mimicking tumor acidic and hypoxic microenvironment in vitro towards generation of more predictive screening platform for solid tumors

Abstract 320: Perfused 3D Tri-Culture Breast Cancer Microtumors for Accurate Prediction of Drug Response

Abstract 4703: Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA

Abstract 4303: High-throughput 3D tumoroid models for immunotherapy and drug discovery

Abstract 2047: Scale up and scale down approaches for screening of 3D patient-derived cell models

Abstract 6782: 3D-EXpress - an ex vivo platform using viably cryopreserved tumoroids for rapid assessment of targeted therapeutic outcomes

Abstract 4250: Adherent and spheroid cell models of patient-derived xenograft for drug development and translational research

Abstract 2060: Automation of 3D cancer spheroid assay for compound screening

Abstract 4258: An innovative PDX and patient-derived 3D platform for improved translatability of new medical entities

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

Abstract 1880: High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities

Abstract 6015: Comprehensive evaluation of three-dimensional (3D) culture systems as compound screening platforms with primary cancer cell lines

Abstract 221: Novel organotypic patient derived primary tumor tissues for oncology drug safety and efficacy studies

Abstract 6790: Breaking barriers: A high-throughput 3D drug discovery platform for ovarian cancer

Abstract 4570: Expanding the 3D ex vivo patient tissue platform toolbox for (immuno)-oncology drug testing

Abstract 314: Micropatterning supported method for cancer spheroid assays under flow and high throughput CAR-T cell potency assay with single cell resolution

Abstract A020: The highly predictive 3D Cell Co-Culture Model for Immunotherapy studies

Abstract 4257: A novel 3D co-culture platform for patient-specific immune-oncology treatment

Abstract 651: 3D-bioprinted cancer models for target discovery, drug development, and personalized therapy

Abstract 6773: Tissue engineered colorectal cancer microspheres for drug screening